Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

14 Customer Reviews

  • Tumor growth of 827 GSC-derived xenografts treated with an AKT inhibitor perifosine (30 mg/kg body weight). Twenty-three days after tumor implantation in mice, perifosine was administered by intraperitoneal injection (daily for 5 days). Error bars represent SD. Five mice per group, *p < 0.01.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    Immunoblot analysis of pY-STAT3, EZH2, AKT, and trimethylated H3K27 in lysates from xenograft tumors treated with an AKT inhibitor perifosine.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • Co-IP analysis of methylated STAT3 in GBM xenograft tumors treated with perifosine.AKT inhibition in vivo decreased STAT3 methylation and pY-STAT3, but increased global levels of H3K27 trimethylation.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    IF staining of pS21 EZH2 and pY-STAT3 on the frozen sections of GBM xenografts treated with vehicle or perifosine. Nuclei were stained with DAPI. Bar represents 10 microns.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • NRP-152 cells were transfected with Id1-luciferase reporter element as described in the figure and then incubated with±perifosine (10 nmol/L)  for 2 hours, followed by±LR3-IGF-I (10 nmol/L) for 24 hours. Cells were then treated with ±BMP4 and assayed for luciferase 2 hours later.

     

     

    Cancer Res 2010 70, 9106-9117. Perifosine (KRX-0401) purchased from Selleck.

     

    LAT2 is degraded by proteasomes after treatment with alkylphospholipids. A, 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 μM) prevented the reduction of LAT2 induced by 25 μM ODPC. B, C, a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 μM) followed by treatment with 25 μM ODPC (B) or 25 μM perifosine (C).

    Mol Cell Proteomics 2012 11(12), 1898-1912 . Perifosine (KRX-0401) purchased from Selleck.

  • Alkylphospholipid-induced morphological changes in HepG2 cells. Cell morphology was examined with an inverted microscope(20× original magnification). The morphology of HepG2 cells incubated with MEM/10% FBS is shown in the absence of any addition (control, A), or in the presence of 25 μM of HePC (B), edelfosine (C), ErPC (D) or perifosine (E) for 24 h. ErPC, erucylphosphocholine; FBS, fetal bovine serum; HePC, hexadecylphosphocholine; MEM, minimal essential medium.

     

     

    Brit J Pharmacol 2010 160, 355–366. Perifosine (KRX-0401) purchased from Selleck.

    Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting analysis demonstrating Ser473p-Akt and total Akt levels in HepG2 cells and Bel-7402 cells treated with increasing concentrations of perifosine for 24 h. Betaactin served as loading control. Bands were analyzed by Glyco Band-Scan software. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05,** P<0.01 vs. control, Student,s t test

     

     

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    Induction of apoptosis in hepatoma cells by treatment for 48 h with 10 μM perifosine. The treated cells were stained with DAPI and the apoptotic morphological changes in the nuclear chromatin were observed under a fluorescent microscope.

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting assay showing cleavage of caspase-3, caspase-9 and PARP in response to perifosine treatment in hepatoma cells. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05, ** P<0.01 vs. control, Student,s t test

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    This chart showed the change of the stable transfection cells in centrosome separation after the cells were treated with perifosine(1 μM)  6 hours, 12 hours and 24 hours. "C" means the control group, and "P" means the group treated with perifosine

    2010 Zhao Jing PHD Medical College of Peking University. Perifosine (KRX-0401) purchased from Selleck.

  • TEIF (telomerase transcriptional elements-interacting factor)gene is a novel human gene and cloned from the expression library of  HeLa cell through the hTERT promoter-based yeast one-hybrid assay. And now we are trying to find the interaction between TEIF and the EGF pathway.

     

     

    2010 Zhao Jing PHD Medical College of Peking University . Perifosine (KRX-0401) purchased from Selleck.

     After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Perifosine for 3h,followed by 15-minute  stimolation of 100ng/ml EGF.

     

     

     

    2010 Dr. Zhang of Tianjin Medical University. Perifosine (KRX-0401) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  MUDGeY5kfGmxbjDBd5NigQ>? MnPnNE42NzFxMj61JO69VQ>? MV6zJIg> M1vRVpJm\HWlZYOgeIhmKGKjc3HsJGNDKHS7cn;zbY5mKHCqb4PwbI9zgWyjdHnvckBt\X[nbIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXyyOlA6Pzh5Mx?=
T24 BC  MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmTFNE42NzFxMj61JO69VQ>? NXrTTYh{OjRiaB?= M17ObIVvcGGwY3XzJJNwemGoZX7pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHTlZ5Jm[XOn MmnTNlYxQTd6N{O=
T24 BC  M37OT2Fxd3C2b4Ppd{BCe3O|YYm= NXjQcWJxOi53IN88US=> NH7aWIUzPCCq Mn[3d4Vve2m2aYrld{BDSyClZXzsd{B1dyC|b4Lh[oVvcWJvaX7keYNm\CCjcH;weI91cWQEoB?= MmexNlYxQTd6N{O=
HepG2 MVXGeY5kfGmxbjDBd5NigQ>? NI\ySYwzOMLizszN Mne2NlTDqGh? M1rreZBzd2S3Y3XzJIFvKGmwdHXud4Uh[3m2b4DsZZNucWNidnHjeY9tcXqjdHnvckBkd3K{ZYPwc45lcW6pIITvJIEhdm:2YXLs[UBlcWyjdHH0bY9vKG:oIITo[UBGWiClaYP0[ZJvew>? NITqNWgzPTl|NEKzNi=>
U-87 MG  NX;1XmhZTnWwY4Tpc44hSXO|YYm= NWPsbHNUOjEEoN88US=> NG\PeHIzPMLiaB?= NGLSSoJqdmO{ZXHz[ZMh\G:3YnzlMY1mdWK{YX7lJIJwfW6mIIP0dpVkfHW{ZYO= M2Lp[lI2QTN2MkOy
HepG2 M{DmSmZ2dmO2aX;uJGF{e2G7 MmHVNlDDqM7:TR?= NGLVXVc3NzJ2IHi= NEKzUodqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDMR|MuUUliY3;0doVifGWmIIfpeIghS1F? Mlz3NlU6OzR{M{K=
U-87 MG  NX7IXZZRTnWwY4Tpc44hSXO|YYm= MoK4NlDDqM7:TR?= NIfxdZY3NzJ2IHi= M3f2TYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFzDN{1KUSClb4Ty[YF1\WRid3n0bEBEWQ>? NUPkRXRMOjV7M{SyN|I>
HepG2 MYTGeY5kfGmxbjDBd5NigQ>? NGXvSFczOMLizszN M13t[FYwOjRiaB?= NUTCdVc1\GWlcnXhd4V{KEyFMz3JTUBl\We{YXTheIlwdsLiZoLvcUA3KGh? MlLRNlU6OzR{M{K=
U-87 MG  NXi1bpM6TnWwY4Tpc44hSXO|YYm= NHzxVmUzOMLizszN NXfTTFFEPi9{NDDo Mn\pbY5kemWjc3XzJJRp\SCjdYTvdIhi\2mlIH\seZghKGG2IE[gbEB4cGmuZTDpcohq[mm2czD0bIl{KG[udYigZZQhOjSq MkjsNlU6OzR{M{K=
HepG2 NGXjeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjqdoQ5OjBxNECg{txO M2XjeFI1NzR6IHi= MmfRbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MUSyOVk{PDJ|Mh?=
U-87 MG  NYPXWVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPldmIzOC92MDFOwG0> NFHDeXczPC92ODDo MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NWDjRYJUOjV7M{SyN|I>
A549 NH33UlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37CPVAvOy1zMDFOwG0> MmjLNlQwPzJiaB?= NUfoTIt3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M1HoVVI2Pjl5OEm5
H460 MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rRZ|AvOy1zMDFOwG0> MW[yOE84OiCq MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MVGyOVY6Pzh7OR?=
A549 NGLhNXlCeG:ydH;zbZMhSXO|c3H5 NXviNHBSOS9|IN88US=> MU[0PEBp MnjSbY5lfWOnczDhdI9xfG:|aYO= MXyyOVY6Pzh7OR?=
H460 NFXlZYZCeG:ydH;zbZMhSXO|c3H5 M4j2blEwOyEQvF2= NI\s[FE1QCCq NVnQSlB7cW6mdXPld{BieG:ydH;zbZM> MmDoNlU3QTd6OUm=
A549 NXPUeZNVTnWwY4Tpc44hSXO|YYm= NEPQT3A{KM7:TR?= NVLkfmpuQCCq NFzkPZpjdG:la4OgRWtVKGGldHn2ZZRqd25? MoLPNlU3QTd6OUm=
H460 NITZNYJHfW6ldHnvckBCe3OjeR?= NUDEXGVmOyEQvF2= M2fxdVghcA>? M4PvRoJtd2OtczDBT3Qh[WO2aY\heIlwdg>? MnvYNlU3QTd6OUm=
A549 MmjlSpVv[3Srb36gRZN{[Xl? Mk\2N{DPxE1? M4\0WVghcA>? NXSxendj[myxY3vzJI1VV1KFMTygZY5lKEWUSz3NRXBMKGGldHn2ZZRqd25iY3;tZolv\WRid3n0bEBOTUtvMU[y NHHWT4IzPTZ7N{i5PS=>
H460 MorFSpVv[3Srb36gRZN{[Xl? MVSzJO69VQ>? MX[4JIg> NYHtXlk{[myxY3vzJI1VV1KFMTygZY5lKEWUSz3NRXBMKGGldHn2ZZRqd25iY3;tZolv\WRid3n0bEBOTUtvMU[y NHfaWGQzPTZ7N{i5PS=>
RMG1 NH7CZllE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MofsNU0{OCEQvF2= NV3VbXpLPzJiaB?= NILNR2tl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MoPoNlU2OTlzNEi=
RMG2 Mnn5R4VtdCCYaXHibYxqfHliQYPzZZk> MnHQNU0{OCEQvF2= NHf1N4w4OiCq M2XSXYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M1nsXlI2PTF7MUS4
KOC7C MnX1R4VtdCCYaXHibYxqfHliQYPzZZk> M{H3PVEuOzBizszN M4nsN|czKGh? MYPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MniwNlU2OTlzNEi=
HAC2 NEnQXYRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{n5WlEuOzBizszN MUO3NkBp MnW3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M2L4WVI2PTF7MUS4
RMG2 M{XkTGNmdGxiVnnhZoltcXS7IFHzd4F6 NEnvOHYyNTNyIN88US=> MYS0PEBp NFf0Z5ll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M3;5eFI2PTF7MUS4
OVISE M3XM[GNmdGxiVnnhZoltcXS7IFHzd4F6 MWGxMVMxKM7:TR?= M{LoSVQ5KGh? NEmwR2Jl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MkfxNlU2OTlzNEi=
SKOV3 Ml;rR4VtdCCYaXHibYxqfHliQYPzZZk> MWixMVMxKM7:TR?= NITlTI81QCCq M1XZb4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NHnuPVIzPTVzOUG0PC=>
A2780 NInDTYRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnTINU0{OCEQvF2= M3\G[VQ5KGh? MkC1[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M2eyeFI2PTF7MUS4
RMG1 MVrBdI9xfG:|aYOgRZN{e2G7 NWT0N3VKOzBizszN Mmj3NlQhcA>? M4DmbYlv\HWlZYOgZZBweHSxc3nz MYSyOVUyQTF2OB?=
RMG2 MVjBdI9xfG:|aYOgRZN{e2G7 MlnMN|Ah|ryP NUiwNnZJOjRiaB?= MmXCbY5lfWOnczDhdI9xfG:|aYO= Ml7XNlU2OTlzNEi=
HCC1806 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISwdFcxNTFyIN88US=> NHnaZoI1QCCq M3nmbmVEPTB;Mj64OQKBkcLz4pEJNE4xPyEQvF2= NYjsXnNGOjV{OUO1O|Y>
MDA-MB-231  MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XuZ|AuOTBizszN NWXwdGp4PDhiaB?= MVfFR|UxRTFwMURihKnDueLCiUCuNFch|ryP MkHTNlUzQTN3N{[=
GL-1 NUPYXIhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjD[IR1OC5z4pETNVAx6oDLzszN MnjtOFghcA>? NFrLU|NKSzVyPUmuPVEh|ryP NF3WSmwzPDh6MUWwPC=>
CLBL-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoeyNE4y6oDVMUCw5qCK|ryP M1XIelQ5KGh? M3\UOWlEPTB;M{OuNEDPxE1? M37ueFI1QDhzNUC4
UL-1 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPrNE4y6oDVMUCw5qCK|ryP MUe0PEBp NUnGcWVKUUN3ME23MlAyKM7:TR?= Mnu1NlQ5QDF3MEi=
Ema M4j6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17YSFAvOeLCk{GwNQKBkc7:TR?= Mn;tOFghcA>? NF;oSZZKSzVyPUW4Mlch|ryP NYXteoRFOjR6OEG1NFg>
PANC-1 M3LFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrYdHNjOC1{NTFOwG0> MlnIO|IhcA>? MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NYnDdZVsOjR3MUm3OVE>
MIA NYXDNVdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWwMVI2KM7:TR?= NYLieXo4PzJiaB?= NXz0dXlFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXzjWXozOjR3MUm3OVE>
AsPC-1 NYLzRVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\HS5ExNTJ3IN88US=> NVz4TFQxPzJiaB?= NYi3UHc4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M3vSZlI1PTF7N{Wx
PANC-1 MnXDSpVv[3Srb36gRZN{[Xl? MUOwMlUh|ryP MlizNlQhcA>? MVnpcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> NHi2XVYzPDVzOUe1NS=>
MIA MVLGeY5kfGmxbjDBd5NigQ>? Mnm1NE42KM7:TR?= NXf6U5czOjRiaB?= NWfmU5pGcW6qaXLpeJMhSWu2LDDTOmsyNCCjbnSgSZJsOS9{IIDoc5NxcG:{eXzheIlwdsLi M1\EO|I1PTF7N{Wx
AsPC-1 NUfWc3k2TnWwY4Tpc44hSXO|YYm= NUjlZppIOC53IN88US=> MmL4NlQhcA>? MXLpcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> MYmyOFUyQTd3MR?=
U87MG NX72WI5bS2WubDDWbYFjcWyrdImgRZN{[Xl? NFy1NFUxNTJ3IN88US=> NXfuWlZLOjRvOU[gbC=> NHWyNopl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> Ml3jNlQxPjV3MkK=
SGC7901  NE\ib|dHfW6ldHnvckBCe3OjeR?= NUCwbnR3OC55NT:xNOKh|ryP NIm3XFE1QCCq MofO[IVkemWjc3XzJJAuSWu2IDjT[ZIhPDd|KTygdE1IW0t|zsKgLHNmeiB7KTygZY5lKENvTWnDJIxmfmWuc9Mg M2HLOlI{QTF{MkS2
MGC803  MYTGeY5kfGmxbjDBd5NigQ>? NI\6TogxNjd3L{GwxsDPxE1? NW\ndlZ{PDkEoHi= Mojk[IVkemWjc3XzJJAuSWu2IDjT[ZIhPDd|KTygdE1IW0t|zsKgLHNmeiB7KTygZY5lKENvTWnDJIxmfmWuc9Mg MlvkNlM6OTJ{NE[=
TykNu NUW3dIxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHRTWM2OD1|LkWg{txO M1vKR|I{QDd5MEGy
TykNuR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTVwNTFOwG0> M3vkOFI{QDd5MEGy
M41 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfwTWM2OD1{ND63JO69VQ>? Mkn0NlM5PzdyMUK=
M41R MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF7Lkig{txO M1XqXFI{QDd5MEGy
OVCAR8 M2nyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfhZmRKSzVyPUOxMlEh|ryP NFHXT|kzOzh5N{CxNi=>
HeyA8 NVr0dXJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\BS49UUUN3ME2yOE4{KM7:TR?= NX;0VGhWOjN6N{ewNVI>
A2780CP NIn6b45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTdwNjFOwG0> Mk\CNlM5PzdyMUK=
OVCAR5 M3vNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTZwNzFOwG0> MnPMNlM5PzdyMUK=
A2780S M1T3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf2d2V{UUN3ME2xOE42KM7:TR?= MXeyN|g4PzBzMh?=
MCAS M176fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvPTWM2OD1zMj61JO69VQ>? NYXMRY1NOjN6N{ewNVI>
NCI-H727 MUHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX3zXnhwOC1zMECg{txO NHKzZpgzPC95MjDo MYfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NEfGOXIzOjR7OUSzOy=>
GOT1 NIm2dnhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYTlZmxmOC1zMECg{txO MnraNlQwPzJiaB?= NWnqNmUx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MVOyNlQ6QTR|Nx?=
BON1 NF7TOFFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUSwMVExOCEQvF2= NF3XZ2MzPC95MjDo M3TkVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MmX2NlI1QTl2M{e=
BON1 NGq1XZRCeG:ydH;zbZMhSXO|c3H5 M{jiNVAuOTBizszN NXvNVFFHOjRiaB?= NGraTJNqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NHiwd|AzOjR7OUSzOy=>
BON1 MWjGeY5kfGmxbjDBd5NigQ>? NG\HS2s4NjVxMUCg{txO MXO4JIg> MVjk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[geIhmKGGwdHmtZZBweHSxdHnjJJBzd3SnaX7zJGJEVDJiYX7kJGJkdC2[TB?= NYDGXJpiOjJ2OUm0N|c>
Kasumi-1 MkLnR4VtdCCYaXHibYxqfHliQYPzZZk> MlHqNE0zOCEQvF2= NEfofHczPC92ODDo MlTD[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MV6yNlQxPzJ{OB?=
HL-60 NHT2SplE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlLkNE0zOCEQvF2= NIS1R3AzPC92ODDo NWDkUFJi\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MkTRNlI1ODd{Mki=
Kasumi-1 NHGw[Y1CeG:ydH;zbZMhSXO|c3H5 MX6xNEDPxE1? M2G1XVI1KGh? NWrGemVTcW6mdXPld{BieG:ydH;zbZM> NV\TWZNuOjJ2MEeyNlg>
HL-60 NYDCd2lsSXCxcITvd4l{KEG|c4PhfS=> NUHU[49zOTBizszN NFLrWZozPCCq NGDk[VBqdmS3Y3XzJIFxd3C2b4Ppdy=> NGfYTIIzOjRyN{KyPC=>
Kasumi-1 Mom4SpVv[3Srb36gRZN{[Xl? NXPkdYt4Oi53L{WvNVAh|ryP MWWyOEBp NX36co52\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy|wrDkc5NmNWSncHXu[IVvfGy7 NF;YcIkzOjRyN{KyPC=>
HL-60 NX\jdoZsTnWwY4Tpc44hSXO|YYm= MUmyMlUwPS9zMDFOwG0> M1[xWVI1KGh? MnjB[IVkemWjc3XzJGFsfCCjbnSgdE1Cc3RibHX2[Yx{yqCmb4PlMYRmeGWwZHXueIx6 MXmyNlQxPzJ{OB?=
Kasumi-1 M{i0fWZ2dmO2aX;uJGF{e2G7 M3nDfFIvPS93L{GwJO69VQ>? NUnNN|A{OjRiaB?= MWfpcoR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NY\uTZlKOjJ2MEeyNlg>
HL-60 MlHnSpVv[3Srb36gRZN{[Xl? MV2yMlUwPS9zMDFOwG0> NXO4VI5COjRiaB?= NFK3TY9qdmS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiSl7LNU8zKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NH7CepYzOjRyN{KyPC=>
K562 MYXGeY5kfGmxbjDBd5NigQ>? M{C2PVIxKM7:TR?= NGLTNY41QCCq NXLEO4kzcW6mdXPld{BifXSxcHjh[5nDqA>? MkW5NlI1ODd{Mki=
OCUT1 NX\XN29nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLJWWpMOC5zLUOg{txO NVnTO|lkPSCm MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MVuyNlA6ODJ5MR?=
K1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrOb|VDOC5zLUOg{txO MWW1JIQ> NVvSVI9[cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUO0bW5rOjJyOUCyO|E>
OCUT1 Mlr2SpVv[3Srb36gRZN{[Xl? MUezJO69dQ>? Mkm0NlQhcA>? MlzBZ4F2e2W|IHGg[JJidWG2aXOgbY5kemWjc3WgbY4hTzJxTTDwbIF{\Q>? Mmi1NlIxQTB{N{G=
CaOV3 M2\F[GNmdGxiVnnhZoltcXS7IFHzd4F6 NYH6NGs3OS93L{GwJO69VQ>? NF7vV401QCCq MW\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJiY3;0doVifGWmIIfpeIgheGGlbHn0ZZhmdA>? NH;HPZQzOTd5NUC1OC=>
SKOV3 MnfDR5l1d3SxeHnjbZR6KEG|c3H5 MnqzOUDPxE1? NUfp[ldKPDhiaB?= NXiyVW84\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? MnnaNlE4PzVyNUS=
A2780 M4f2[GN6fG:2b4jpZ4l1gSCDc4PhfS=> MlnuOUDPxE1? MkHhOFghcA>? M1vnPYVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> M2Gx[lIyPzd3MEW0
HT-29  MUDDfZRwfG:6aXPpeJkhSXO|YYm= NHf5Vpk2KM7:TR?= MkDaOFghcA>? M1Gyc4VvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> MVKyNVc4PTB3NB?=
A498 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOwMVQxKM7:TR?= MVW3NkBp NX\YTJV3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NU\6V3UxOjF4NESwOVA>
CAKI-1 NGCyOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTEVmgxNTRyIN88US=> NET5RVE4OiCq MonvTWM2OH5zMDFOwG0> M4XTdlIyPjR2MEWw
769-P MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v0blAuPDBizszN NVzUNplQPzJiaB?= MX\JR|UxhjVvMUCg{txO MV:yNVY1PDB3MB?=
786-0 NGXo[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;XNVAuPDBizszN M2nZUFczKGh? NWLnbVhJUUN3MI61JO69VQ>? NWLGS4lkOjF4NESwOVA>
786-O M3fQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[wMVIxKM7:TR?= NXSzVYFEPzJiaB?= M4SyeIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MoH0NlE3PDRyNUC=
CAKI-1 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHwRWlxOC1{MDFOwG0> NHuyPIc4OiCq NGrMXXZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NFXIfowzOTZ2NEC1NC=>
769-P Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrRNE0zOCEQvF2= NF;jU4Q4OiCq NGLMcFNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Ml\qNlE3PDRyNUC=
A498 M2DD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\UNE0zOCEQvF2= NHrM[m84OiCq NIXVcYxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MnnxNlE3PDRyNUC=
CWR22RV1 NI[3bWlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2LnU|ExKM7:TR?= NXi1S4FwOjRiaB?= NXTEO2c1cW6lcnXhd4V{KHOnboPpeIl3cXS7IH;mJIh2dWGwIFPXVlIzWlZzIHPlcIx{KHSxIILh[IlifGmxbh?= NFX1cJIzOTR7NkK3Ny=>
CWR22RV1 M4XYU2Fxd3C2b4Ppd{BCe3O|YYm= M3KybFExKM7:TR?= MonaNlQhcA>? NFvIWlNmdmijbnPld{Bz[WSrYYTpc44hcW6mdXPl[EBieG:ydH;zbZM> MWqyNVQ6PjJ5Mx?=
CWR22RV1 NWfqTFZ3TnWwY4Tpc44hSXO|YYm= NEnCeYs2KM7:TR?= M{S2TVI1KGh? M1LlcpJm\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGFsfCC|aXfubYZq[2GwdHz5 NVHMRnJsOjF2OU[yO|M>
HepG2  NFXMV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPJOU8yOC9{MD:0NEDPxE1? MUCyOE81QC95MjDo NGj6W21qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MWmyNFg1OjR{NR?=
Bel-7402 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq1M|ExNzJyL{SwJO69VQ>? NYTsNnNLOjRxNEivO|IhcA>? M4nuTYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MkPVNlA5PDJ2MkW=
HepG2  NW\zSnloTnWwY4Tpc44hSXO|YYm= NGjEZXQ2NzFyL{KwJO69VQ>? MYmyOEBp Mm\YdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn NEDz[pozODh2MkSyOS=>
Bel-7402 NEHDflhHfW6ldHnvckBCe3OjeR?= NVy1SI41PS9zMD:yNEDPxE1? NHnldZkzPCCq NFTxOVdz\XO3bITzJIlvKHSqZTDhZ4N2dXWuYYTpc44hd2ZiY3XscEBvfW2kZYKgbY4hfGinIFeyM20heGijc3W= MYeyNFg1OjR{NR?=
HepG2  NUPRPXJXSXCxcITvd4l{KEG|c4PhfS=> M17aRVUwOTBxMkCg{txO NF\UZmkzPC92ODDo NETtTZpqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLl MmnoNlA5PDJ2MkW=
Bel-7402 M2TYdmFxd3C2b4Ppd{BCe3O|YYm= NF7Ybo02NzFyL{KwJO69VQ>? NWjOVWR{OjRxNEigbC=> NIXFSGZqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLl NVvXbpZoOjB6NEK0NlU>
OAW-42 M{\M[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M163b|AuPDBizszN Mo\EO|LDqGh? NXfvRZZOUUN3MI6xNEDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NXnybpExOjB2MEWyPVY>
PA-1  NVG3dGpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LuUVAuPDBizszN NWS1XYF2PzMEoHi= MmLLTWM2OH5{NTFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MUiyNFQxPTJ7Nh?=
SKOV3  NV61T4dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\nTFExNTRyIN88US=> NVjMNnJKPzMEoHi= NHPleZpKSzVyfkOwJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NFWwdYIzODRyNUK5Oi=>
A2780 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:2Z4sxNTJyIN88US=> MXi0PE84OiCq NFKyT2lKSzVywrC9xsA{yqEQvH2= NEPncZAzODRyNUK5Oi=>
A2780cis  M4PXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTMb49IOC1{MDFOwG0> NIjEXGM1QC95MjDo NWfEcW9lUUN3MNMgQeKhPsLizszt MVuyNFQxPTJ7Nh?=
SKW6.4 M3[2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDEeWczNTFywrFOwG0> NHX4NXE1QMLiaB?= Moq3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NULoO|dTOjBzM{C5OlA>
MAVER NEXqVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvU[4pGOi1zMNMg{txO MkC2OFjDqGh? NF7JPHJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NUPYbJN4OjBzM{C5OlA>
BJAB MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MViyMVExyqEQvF2= NVXzVG1FPDkEoHi= Ml;3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MoPyNlAyOzB7NkC=
OCI NIfTcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojBNk0yOMLizszN NFjL[nM1QMLiaB?= M4XIbolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NF;VfpUzODF|MEm2NC=>
MOLM NIrnbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGyMVExyqEQvF2= MVG0POKhcA>? MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXzxUXV2OjBzM{C5OlA>
HL-60 MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzsW3QzNTFywrFOwG0> NIryV4Y1QMLiaB?= NETXWlZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHHUenozODF|MEm2NC=>
SKW6.4 MV\BdI9xfG:|aYOgRZN{e2G7 NETJVnUyOMLizszN NFTyPJUzPC92ODDo M1vGdolv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= NXu1NZpwOjBzM{C5OlA>
MAVER M3PjV2Fxd3C2b4Ppd{BCe3O|YYm= NXu0NWZnOTEEoN88US=> NUH2ZnZjOjRxNEigbC=> M{jLVIlv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= M2\vTlIxOTNyOU[w
BJAB NX7hbGFpSXCxcITvd4l{KEG|c4PhfS=> MmPPNVDDqM7:TR?= NYfsc5E2OjRxNEigbC=> NUfMSWlJcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> M3;NV|IxOTNyOU[w
OCI NGfpeHdCeG:ydH;zbZMhSXO|c3H5 NGDyeXoyOMLizszN NUC2cY5lOjRxNEigbC=> Mn7tbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= MmnVNlAyOzB7NkC=
MOLM NInXcmdCeG:ydH;zbZMhSXO|c3H5 M1jkNlExyqEQvF2= MYSyOE81QCCq MULpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 NHnReXEzODF|MEm2NC=>
HL-60 M1La[GFxd3C2b4Ppd{BCe3O|YYm= MnLuNVDDqM7:TR?= NFvpPHYzPC92ODDo NEDEbXVqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 MoPVNlAyOzB7NkC=

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02238496 Recruiting Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Active, not recruiting Cancer AEterna Zentaris January 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Active, not recruiting Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01051557 Active, not recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 2010 Phase 1|Phase 2
NCT01002248 Terminated Multiple Myeloma AEterna Zentaris|Dana-Farber Cancer Institute December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID